Fintel reports that on May 9, 2023, HC Wainwright & Co. reiterated coverage of Annexon (NASDAQ:ANNX) with a Buy recommendation.
Analyst Price Forecast Suggests 252.49% Upside
As of April 24, 2023, the average one-year price target for Annexon is 18.51. The forecasts range from a low of 8.08 to a high of $31.50. The average price target represents an increase of 252.49% from its latest reported closing price of 5.25.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Annexon is 0MM. The projected annual non-GAAP EPS is -2.23.
What is the Fund Sentiment?
There are 138 funds or institutions reporting positions in Annexon. This is an increase of 7 owner(s) or 5.34% in the last quarter. Average portfolio weight of all funds dedicated to ANNX is 0.30%, a decrease of 6.39%. Total shares owned by institutions increased in the last three months by 2.37% to 53,414K shares. 
The put/call ratio of ANNX is 0.50, indicating a bullish outlook.
What are Other Shareholders Doing?
Bain Capital Life Sciences Investors holds 4,887K shares representing 9.21% ownership of the company. In it's prior filing, the firm reported owning 3,602K shares, representing an increase of 26.29%. The firm increased its portfolio allocation in ANNX by 6.25% over the last quarter.
Satter Management Co. holds 4,409K shares representing 8.31% ownership of the company. No change in the last quarter.
Bvf holds 3,781K shares representing 7.12% ownership of the company. No change in the last quarter.
Eventide Asset Management holds 3,627K shares representing 6.83% ownership of the company. No change in the last quarter.
ETAHX - Eventide Healthcare & Life Sciences Fund Shares holds 3,627K shares representing 6.83% ownership of the company. No change in the last quarter.
Annexon Background Information
(This description is provided by the company.)
Annexon, Inc., doing business as Annexon Biosciences, operates as a clinical-stage biopharmaceutical company. The Company develops novel therapies for auto-immune and neurodegenerative diseases of body, eye, and brain. Annexon Biosciences serves patients in the State of California.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
